Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Open-label Phase 2 Study of Low Dose Dacogen® for Injection (Decitabine) in Patients With Low or Intermediate 1 Risk Myelodysplastic Syndromes

NCT00619099 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00619099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00619099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Open-label Phase 2 Study of Low Dose Dacogen® for Injection (Decitabine) in Patients With Low or Intermediate 1 Risk Myelodysplastic Syndromes
Lead sponsor
Eisai Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2008
Completion date
Not reported
Enrollment
67 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome